Tyrosine-derived polyesteramide antimicrobial composition for sternal wound infection prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing mediastinitis, particularly in patients post-median sternotomy or esophageal perforation, are inadequate as they often rely on prophylactic antibiotics which are not effective in reducing sternal wound infections and may contribute to antibiotic resistance, and haemostatic agents like bone wax can enhance infection and inhibit bone growth.
Innovation Solution
A topical composition comprising a tyrosine-derived polyesteramide and at least one antimicrobial agent, such as minocycline and rifampin, is applied to the sternum or esophageal perforation site, providing a bioresorbable barrier that inhibits bacterial colonization and promotes bone growth, reducing the incidence of mediastinitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prophylactic antibiotics are administered, then infection risk is reduced, but antibiotic resistance develops and sternal wound infections are not effectively prevented
Solution Approach 1:
The patent applies antimicrobial agents to the sternal wound site before closure during surgery, establishing protective concentration in advance before bacterial contamination can occur. This preliminary action prevents infection without requiring postoperative antibiotics, thereby avoiding antibiotic resistance development.
Solution Approach 2:
The patent delivers antimicrobial agents directly to the sternal wound site through topical application or incorporated materials, creating high local concentration where needed while avoiding systemic administration. This localized approach prevents infection effectively without contributing to widespread antibiotic resistance.
2Stress or pressure
If bone wax is used as a haemostatic agent, then bleeding is controlled, but infection is enhanced and bone growth is inhibited
Solution Approach 1:
The patent removes bone wax from the surgical procedure entirely, replacing it with alternative haemostatic methods that do not possess inflammatory properties. This extraction eliminates the harmful effect of infection enhancement while maintaining haemostasis through other means.
Solution Approach 2:
The patent introduces antimicrobial-impregnated materials or topical antimicrobial agents as intermediary substances that provide both haemostatic support and infection protection without the harmful inflammatory properties of bone wax. These intermediaries mediate between haemostasis and infection prevention.
3Reliability
If IV antibiotics are administered, then systemic infection is treated, but high local concentration at the sternal wound site is not achieved
Solution Approach 1:
The patent transitions from systemic IV antibiotic administration to localized topical application or incorporated delivery at the sternal wound site. This creates high local concentration of antimicrobial agents exactly where needed, achieving both systemic protection and localized efficacy simultaneously.
Solution Approach 2:
The patent replaces the mechanical circulation-based delivery system (IV administration relying on blood flow) with direct local application or incorporated delivery systems. This substitution ensures high local concentration is achieved through direct placement rather than relying on circulatory distribution.
4Ease of manufacture
If standard wound closure is performed, then surgical access is restored, but sternal wound infections occur and track to the bony sternum
Solution Approach 1:
The patent incorporates antimicrobial agents into the wound closure materials themselves, creating composite materials that provide both structural closure function and antimicrobial protection. This integration prevents infection tracking to the bone while maintaining effective wound closure.
Solution Approach 2:
The patent applies antimicrobial protection during the closure process itself, establishing defensive concentration before bacteria can track to the bone. This preliminary antimicrobial action prevents infection progression while the closure restores surgical access.
Data Source
Figure 1~2
Figure 3~4
AI summary
The invention generally relates to compositions and methods for preventing sternal wound infections, such as mediastinitis. In certain embodiments, the invention provides an antimicrobial composition including at least one bioresorbable polymer, such as a tyrosine-derived polyesteramide, and at least one antimicrobial agent, in which the composition is adapted to be topically applied to an esophageal perforation in a subject or a median sternotomy incision site in the subject, and in which the at least one antimicrobial agent is present in an amount effective to inhibit development of mediastinitis in the subject.